Search

Supplemental Material for Over-Expression of ARID3B Suppresses Tumor Progression and Predicts Better Prognosis in Patients With Gastric Cancer by Xunlei Zhang, Xinyue Qiu, Wenjing Zhao, Li Song, Xingsong Zhang, Lei Yang, and Min Tao in Cancer Control.

Supplemental material, sj-docx-1-tia-10.1177_23312165221134007 for Development and Validation of a Mandarin Chinese Adaptation of AzBio Sentence Test (CMnBio) by Xin Xi, YeWang, Ya Shi, Rui Gao, Siqi Li, Xinyue Qiu, Qian Wang, and Li Xu in Trends in Hearing

Supplemental material, sj-docx-1-tia-10.1177_23312165221134007 for Development and Validation of a Mandarin Chinese Adaptation of AzBio Sentence Test (CMnBio) by Xin Xi, YeWang, Ya Shi, Rui Gao, Siqi Li, Xinyue Qiu, Qian Wang, and Li Xu in Trends in Hearing

Gastric cancer (GC) is one of the most common malignancies in the world. It is also the fifth most common cancer in China. In recent years, a large number of studies have proved that non-coding RNAs (ncRNAs) can regulate cell proliferation, invasion, metastasis, apoptosis, and angiogenesis. NcRNAs also influence the therapeutic resistance of gastric cancer. NcRNAs mainly consist of miRNAs, lncRNAs and circRNAs. In this paper, we summarized ncRNAs as biomarkers and therapeutic targets for gastric cancer, and also reviewed their role in clinical trials and diagnosis. We sum up different ncRNAs and related moleculars and signaling pathway in gastric cancer, like Bcl-2, PTEN, Wnt signaling. In addition, the potential clinical application of ncRNAs in overcoming chemotherapy and radiotherapy resistance in GC in the future were also focused on.